who medicines strategy - libdoc.who.int - World Health Organization

More documents

Recommendations

Info

WHO MEDICINES STRATEGY 2004-2007 | 56In high-income countries, average percapita spending on pharmaceuticalsis 100 times more than in low-incomecountries – about US$ 400 compared withabout US$ 4. At the opposite ends of thespectrum, there is a 1000-fold differencebetween what the highest spending andlowest spending countries spend onpharmaceuticals.Source: WHO National Health AccountsCOMPONENT 3SUSTAINABLE FINANCINGMECHANISMS FOR MEDICINES
COMPONENTS OF THE STRATEGY | 57Figure 13:Financing medicines: the Uganda experienceUS$2.30 gap translates into – US$4.00 - US$5.00 in out-ofpockethousehold expenditures on drugs14%8%66%12%GAPPROJECTCENTRALED kits = US$0.08 per capitaDECENTRALIZEDAdequate and sustainable financing of medicinesremains a remote prospect for almost half of theworld’s population.Since 1995, private sources of finance forpharmaceuticals have become more importantin all countries, with attendant risks to publichealth objectives. Governments’ share inpharmaceutical spending has fallen faster thantheir share in total health spending. Whileexternal assistance has boosted pharmaceuticalspending in a small number of countries, mostcountries with high HIV/AIDS mortality arestill spending less than US$ 5 per capita onmedicines.Both published studies and WHO NationalHealth Accounts confirm that pharmaceuticalsexpenditure in developing countries accountsfor 25%-65% of total public and private healthexpenditure, and for 60%-90% of out-of-pockethousehold spending on health. 21In Uganda, it was estimated that annual percapita medicine needs in 2002-2003 were US$3.50. Figure 13 shows that the available fundsfrom local, central, and externally funded projectsources totalled only US$1.20 per capita, leavingUS$2.30 per capita — or two-thirds of thefinancial resources for medicines — to be metfrom household sources. From these figures it wasestimated that a typical household’s out-of-pocketspending on medicines would have to be betweenUS$4 and US$5 for needs to be met. Such aheavy financial burden will obviously hit poorerhouseholds hardest.A much greater role for public finance is needed,involving both developing country governmentsand international donors. In addition, increasedefficiency in public finance is needed in order toexpand access to essential medicines.In view of the heavy burden ofmedicines expenditure, especiallyin developing countries, and theunique aspects of managing thiscritical health resource, WHOprovides guidance on financingthe supply of medicines, in aneffort to increase the affordabilityof essential medicines in both thepublic and private sectors.
Page 10 and 11:
WHO MEDICINES STRATEGY 2004-2007 |x
Page 12 and 13:
WHO MEDICINES STRATEGY 2004-2007 |x
Page 14 and 15:
WHO MEDICINES STRATEGY 2004-2007 |
Page 23: MEDICINESAND PUBLIC HEALTH
Page 26 and 27: WHO MEDICINES STRATEGY 2004-2007 |
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 157 and 158:
REFERENCES
Page 159 and 160:
REFERENCES | 1471Annual report 2000
Page 161 and 162:
REFERENCES | 14912 th Model List of
show all

who medicines strategy - libdoc.who.int - World Health Organization

Create successful ePaper yourself

Delete template?

Save as template?